ERCC6L2: A Potential Drug Target and Biomarker for DNA Excision Repair

Target Name: ERCC6L2

NCBI ID: G375748

ERCC6L2

ERCC6L2: A Potential Drug Target and Biomarker for DNA Excision Repair

DNA excision repair is a crucial process in the cell that ensures the integrity of genetic information. DNA repair deficiencies can lead to various diseases, including cancer. The protein ERCC-6-like 2 (ERCC6L2) is an isoform of the DNA excision repair protein ERCC-6 that has been identified as a potential drug target and biomarker. In this article, we will explore ERCC6L2 and its potential as a drug target and biomarker.

ERCC6L2: Structure and Function

ERCC6L2 is a 21-kDa protein that belongs to the ERCC-6 family of proteins. This protein is involved in the DNA repair pathway, specifically in the excision repair of double-stranded breaks in DNA. excision repair is a process that involves the removal of a double-stranded break and the formation of a single-stranded repair copy. ERCC6L2 plays a crucial role in this process by interacting with the enzyme responsible for the repair of double-stranded breaks, called DNA polymerase.

ERCC6L2 has been shown to have various functions, including but not limited to:

* Protecting against radiation-induced DNA damage
* Promoting DNA repair in response to DNA damage
* Regulating DNA replication in the cell
* Involved in the development and progression of certain cancers

ERCC6L2 is also a potent drug target and has been shown to inhibit the activity of various drugs, including chemotherapy drugs, which are often used to treat cancer. This suggests that ERCC6L2 may be a useful biomarker for the diagnosis and treatment of cancer.

ERCC6L2 as a Potential Drug Target

ERCC6L2 has been shown to interact with various drug targets, including but not limited to:

* CDK4
* PDGF-未
* NF-kappa-B
* TGF-β

These interactions suggest that ERCC6L2 may be a potential drug target for various diseases, including cancer. For example, inhibiting the activity of ERCC6L2 has been shown to be effective in treating certain types of cancer, such as melanoma and breast cancer.

ERCC6L2 as a Biomarker

ERCC6L2 has also been shown to serve as a biomarker for various diseases, including cancer. For example, high levels of ERCC6L2 have been shown to be associated with the development of certain types of cancer, such as melanoma and breast cancer. Additionally, studies have shown that inhibiting the activity of ERCC6L2 has been shown to be effective in predicting the outcome of certain types of cancer, such as cancer treatment response.

Conclusion

ERCC6L2 is a protein that plays a crucial role in the DNA repair pathway. Its functions include protecting against radiation-induced DNA damage, promoting DNA repair in response to DNA damage, regulating DNA replication in the cell, and involved in the development and progression of certain cancers. Additionally, ERCC6L2 has been shown to be a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the role of ERCC6L2 in the treatment of cancer and other diseases.

Protein Name: ERCC Excision Repair 6 Like 2

Functions: May be involved in early DNA damage response

The "ERCC6L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERCC6L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets